Recent Updates — LEGN
The U.S. Food and Drug Administration has cleared the Investigational New Drug (IND) application for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy developed by Legend Biotech Corporation. This clearance supports a planned U.S. Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the off-the-shelf single-infusion treatment for relapsed or refractory B-cell malignancies, including non-Hodgkin lymphoma. LB2501 is built on Legend’s proprietary TaVec platform and aims to generate dual-targeting CAR-T cells directly within patients without lymphodepleting chemotherapy. The company operates in the biotechnology sector, specializing in cell therapy innovations such as its marketed product CARVYKTI.
Legend Biotech announced that its product CARVYKTI generated approximately $710 million in net trade sales during the quarter ended September 30, 2026. This figure is based on information provided by collaboration partner Janssen and has not been independently verified or audited by Legend Biotech's accountants. The company operates in the biotechnology industry, focusing on the development of immunotherapies for cancer treatment.
Legend Biotech presented five-year follow-up data from the CARTITUDE-2 Cohort A trial evaluating CARVYKTI (ciltacabtagene autoleucel) in patients with relapsed/refractory multiple myeloma. The study included 20 patients treated after one to three prior lines of therapy, with a median follow-up of 60.7 months. Results showed that 50% of patients remained alive and progression-free without maintenance therapy at five years, while the overall survival rate was 69.2%. The median progression-free survival was 60.5 months. These findings reinforce the durable clinical benefit and potential curative effect of CARVYKTI in earlier-line treatment settings. Legend Biotech is a global leader in cell therapy that develops and markets CAR-T immunotherapies for cancer.
Legend Biotech Corporation appointed Ingrid Zhang as Chief Executive Officer and principal executive officer, effective September 15, 2026. Ms. Zhang succeeds Alan Bash, who served as interim CEO since July 2026 and will resume his role as President of CARVYKTI. Ms. Zhang previously held senior commercial leadership roles at Novartis International, including Chief Commercial Officer and President of China businesses, as well as positions at AstraZeneca, Pfizer, and McKinsey & Company. Her employment agreement includes a $950,000 annual base salary, a target cash bonus of 90% of base salary, an initial restricted stock unit award valued at least $10 million, and a $150,000 signing bonus subject to clawback provisions. Legend Biotech is a global biopharmaceutical company specializing in cell therapy treatments for cancer.